Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 21, 2014; 20(15): 4220-4229
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4220
Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer
Atsuya Takeda, Naoko Sanuki, Etsuo Kunieda
Atsuya Takeda, Naoko Sanuki, Radiation Oncology Center, Ofuna Chuo Hospital, Kanagawa 247-0056, Japan
Etsuo Kunieda, Department of Radiation Oncology, Tokai University, Kanagawa 259-1193, Japan
Author contributions: Takeda A contributed to the manuscript idea, literature search, manuscript writing and final revision of the article; Sanuki N contributed to the manuscript idea and the final revision of the article; Kunieda E contributed to the final revision of the article.
Correspondence to: Atsuya Takeda, MD, PhD, Radiation Oncology Center, Ofuna Chuo Hospital, 6-2-24, Ofuna, Kamakura, Kanagawa 247-0056, Japan. takeda@1994.jukuin.keio.ac.jp
Telephone: +81-467-452111 Fax: +81-467-483197
Received: September 27, 2013
Revised: December 24, 2013
Accepted: February 20, 2014
Published online: April 21, 2014
Core Tip

Core tip: Systemic chemotherapy has enabled prolongation of survival in patients with stage IV colorectal cancer. This has subsequently increased the relative significance of local therapy. Resection is the standard therapy in most settings. Recently, stereotactic body radiotherapy (SBRT) provides high local control with minimal morbidity, both in the curative and palliative setting. The indications of SBRT include liver, lung, isolated lymph nodes, spinal and adrenal metastasis, and post-surgical pelvic recurrence. However, few reports with a high level of evidence have indicated the efficacy of SBRT. Hereafter, the optimal indication of SBRT needs to be prospectively investigated to obtain convincing evidence.